Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Oncology Europe GmbH, Eisai Inc., Pfizer, and Seattle Genetics, Inc.

Community Practice Connections™: 2nd Annual Paris Breast Cancer Conference™

Release Date: January 31, 2019
Expiration Date: January 31, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: 2nd Annual Paris Breast Cancer Conference™ features a summary of clinical evidence guiding the treatment of patients with breast cancer. Topics include the utility of different assays to determine breast cancer relapse risk; recent advancements in the treatment paradigm for patients with luminal breast cancer; current therapeutic options for patients with early-stage and metastatic HER2-positive breast cancer, including the management of brain metastases and patients who are long-term responders to therapy; and emerging therapies for triple-negative breast cancer, such as poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors. This educational activity incorporates didactic reviews of key data accompanied by short video interviews with experts in the field, who share their perspectives on current treatment paradigms, practical patient management insights, and evolving prospects for the future.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Oncology Europe GmbH, Eisai Inc., Pfizer, and Seattle Genetics, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward healthcare professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (eg, physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants) involved in the treatment and management of patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Individualize treatment planning for patients with breast cancer based on the appropriate use and interpretation of biomarker results and molecular or genomic assays
  • Delineate local treatment approaches, such as surgery and radiation therapy, as well as systemic preoperative therapies, to manage patients with early-stage or locally advanced breast cancer
  • Integrate recent clinical trial evidence into personalized treatment strategies for the management of patients with breast cancer
  • Discuss emerging data regarding investigational approaches for managing breast cancer in the context of evolving treatment paradigms
  • Discuss methods to facilitate awareness of clinical trials among patients who may benefit from inclusion in studies evaluating investigation

Faculty, Staff, and Planners' Disclosures


Fabrice André, MD, PhD
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Disclosures: Grant/Research Support: AstraZeneca, Novartis, Pfizer, Lilly, Roche

Judith Balmaña, MD, PhD
Head, Familial Cancer Unit
Assistant Breast Cancer Unit
Vall d’Hebron University Hospital
Barcelona, Spain

Disclosures: Grant/Research Support: PharmaMar; Consultant/Advisory Board: Clovis Oncology, Tesaro; Speakers Bureau: AstraZeneca; Other: PharmaMar reimbursed travel expenses

Javier Cortés, MD, PhD
Head of the Breast Cancer and Gynecological Tumors
Ramón y Cajal University Hospital
Madrid, Spain
Clinical Investigator, Breast Cancer Research Program
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Disclosures: Consultant/Advisory Board: Roche, Celgene, AstraZeneca, Cellestia Biotech, Biothera, Seattle Genetics; Other: Honoraria from Roche, Novartis, Eisai, Celgene, Pfizer

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By